Emir Guven, MD
Endocrinology, Diabetes & Metabolism · Mount Vernon, WANPI 1366493181
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 128 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$885
- Amgen$733
- AstraZeneca$559
- Insulet Corporation$199
- Mannkind Corporation$196
- Chiesi USA, Inc.$195
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,717100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $885 |
| Amgen(2 entities) | 13 | $733 |
| AstraZeneca(2 entities) | 12 | $559 |
| Insulet Corporation | 4 | $199 |
| Mannkind Corporation | 7 | $196 |
| Chiesi USA, Inc. | 3 | $195 |
| Novo Nordisk | 5 | $191 |
| Neurocrine Biosciences, Inc. | 2 | $186 |
| Bayer | 4 | $176 |
| AbbVie | 2 | $147 |
| Tandem Diabetes Care, Inc. | 3 | $143 |
| Radius Health, Inc. | 7 | $139 |
| Xeris Pharmaceuticals, Inc. | 8 | $130 |
| Nevro Corp. | 1 | $114 |
| Gilead | 1 | $95 |
| Lilly USA, LLC | 4 | $95 |
| Boehringer Ingelheim | 4 | $67 |
| Shire North American Group Inc | 1 | $60 |
| Antares Pharma, Inc. | 3 | $58 |
| Dexcom, Inc. | 3 | $45 |
| Recordati_rare_diseases_inc. | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Novartis | 1 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Soleno Therapeutics, Inc. | 1 | $28 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,717 in reported general payments places this provider in the 75th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 36 | $54,716 |
| OzempicSemaglutide | 25 | $28,644 |
| MounjaroTirzepatide | 22 | $27,737 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $24,120 |
| JardianceEmpagliflozin | 33 | $22,567 |
| FarxigaDapagliflozin Propanediol | 17 | $22,518 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $21,410 |
| Cinacalcet Hcl | 19 | $18,521 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $13,022 |
| Novolog FlexpenInsulin Aspart | 17 | $4,939 |
| HumalogInsulin Lispro | 12 | $2,442 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $2,205 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,945 |
| Levothyroxine Sodium | 162 | $1,533 |
| SynthroidLevothyroxine Sodium | 16 | $1,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $95 | $84,89470 claims |
| Novo NordiskOzempic | $191 | $28,64425 claims |
| Boehringer IngelheimJardiance | $67 | $22,56733 claims |
| AstraZenecaFarxiga | $559 | $22,51817 claims |
| AbbVieSynthroid | $147 | $1,35916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Mount Vernon
- Susie NorrisMount Vernon$12K
- Vince MontesMount Vernon$10K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Bruce WilsonRichland$352K
- Irl HirschSeattle$192K
- Biju KunhiramanYakima$118K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.